Journal
International journal of infectious diseases
Publication Date
2-1-2021
Volume
103
First Page
25
Last Page
32
Document Type
Open Access Publication
DOI
10.1016/j.ijid.2020.10.101
Rights and Permissions
Patterson BK, Seethamraju H, Dhody K, Corley MJ, Kazempour K, Lalezari J, Pang APS, Sugai C, Mahyari E, Francisco EB, Pise A, Rodrigues H, Wu HL, Webb GM, Park BS, Kelly S, Pourhassan N, Lelic A, Kdouh L, Herrera M, Hall E, Bimber BN, Plassmeyer M, Gupta R, Alpan O, O'Halloran JA, Mudd PA, Akalin E, Ndhlovu LC, Sacha JB. CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. Int J Infect Dis. 2021 Feb;103:25-32. doi: 10.1016/j.ijid.2020.10.101. © 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recommended Citation
Patterson, Bruce K; Mudd, Philip A; and et al, "CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14." International journal of infectious diseases. 103, 25 - 32. (2021).
https://digitalcommons.wustl.edu/open_access_pubs/11238
Table S1 List of antibodies utilized in this study.
mmc2.xlsx (97 kB)
Table S2 Differentially expressed genes. The table shows all of the genes identified as differentially expressed (Wilcoxon adjusted p < 0.1) in for the contrasts listed.
mmc3_lrg.jpg (129 kB)
Figure S1 COVID-19 plasma viral load lower limit of detection (LOD) determination.
mmc4_lrg.jpg (931 kB)
Figure S2 Complete blood count and serum chemistry values in critically ill COVID-19 patients after leronlimab administration.
mmc5_lrg.jpg (993 kB)
Figure S3 Immunological parameters in critically ill COVID19 patients untreated and treated with leronlimab.
